Cargando…

Evaluation of the Pharmacokinetic Interaction between Lesogaberan (AZD3355) and Esomeprazole in Healthy Subjects

Background: Transient lower esophageal sphincter relaxations (TLESRs) have been identified as a primary cause of reflux events in patients with gastroesophageal reflux disease (GERD). GABAB receptor agonists such as lesogaberan (AZD3355) have been shown to inhibit TLESRs in healthy subjects and pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niazi, Mohammad, Silberg, Debra G., Miller, Frank, Ruth, Magnus, Holmberg, Ann A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2012
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586101/ https://www.ncbi.nlm.nih.gov/pubmed/21171670 http://dx.doi.org/10.2165/11588180-000000000-00000

Ejemplares similares

Pharmacokinetic Profile of Lesogaberan (AZD3355) in Healthy Subjects: A Novel GABA(B)-Receptor Agonist Reflux Inhibitor
por: Niazi, Mohammad, et al.
Publicado: (2012)

Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis
por: Bhattacharya, Dipankar, et al.
Publicado: (2021)

Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study
por: Miner, Philip B, et al.
Publicado: (2014)

Esomeprazole and apixaban pharmacokinetic interactions in healthy rats
por: Jaber, Ali, et al.
Publicado: (2022)

Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs
por: Cook, Emily K, et al.
Publicado: (2016)

Effect of esomeprazole on the pharmacokinetics of carbamazepine
por: Medhi, Bikash, et al.
Publicado: (2011)

Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants
por: Xu, Huiping, et al.
Publicado: (2021)

Pharmacokinetics of Esomeprazole in Critically Ill Patients
por: Xu, Yanyan, et al.
Publicado: (2022)

Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole
por: Bae, Sungyeun, et al.
Publicado: (2021)

Repurposing Lesogaberan to Promote Human Islet Cell Survival and β-Cell Replication
por: Tian, Jide, et al.
Publicado: (2017)

Bioequivalence of two esomeprazole magnesium enteric-coated formulations in healthy Chinese subjects
por: Liu, Zheng-Zhi, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Pharmacokinetics and bioequivalence study of esomeprazole magnesium enteric-coated tablets 20 mg in healthy Chinese subjects under fasting and fed conditions
por: Ding, Ying, et al.
Publicado: (2023)

Effects of Plasma Albumin on the Pharmacokinetics of Esomeprazole in ICU Patients
por: Tian, Hsin, et al.
Publicado: (2018)

The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing
por: Smith, Joe S., et al.
Publicado: (2023)

Corrigendum: Pharmacokinetics and bioequivalence study of esomeprazole magnesium enteric-coated tablets 20 mg in healthy Chinese subjects under fasting and fed conditions
por: Ding, Ying, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of esomeprazole and ranitidine during continuous venovenous hemodiafiltration
por: Fuhrmann, V, et al.
Publicado: (2013)

Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs
por: Seo, Do‐Hyun, et al.
Publicado: (2018)

Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs
por: Hwang, J.‐H., et al.
Publicado: (2017)

Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO(®) (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers
por: Choi, YoonJung, et al.
Publicado: (2015)

Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers
por: Prothon, Susanne, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects
por: Knöchel, Jane, et al.
Publicado: (2021)

Pharmacokinetics and Anti-Gastric Ulceration Activity of Oral Administration of Aceclofenac and Esomeprazole in Rats
por: Kim, Tae Hwan, et al.
Publicado: (2018)

Pharmacokinetics of esomeprazole in goats (Capra aegagrus hircus) after intravenous and subcutaneous administration
por: Fladung, Rachel, et al.
Publicado: (2022)

Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2023)

Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability
por: Ericsson, Hans, et al.
Publicado: (2019)

Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole
por: Kaur Mukker, Jatinder, et al.
Publicado: (2022)

Fabrication of Polymeric Hydrogels Containing Esomeprazole for Oral Delivery: In Vitro and In Vivo Pharmacokinetic Characterization
por: Ullah, Irshad, et al.
Publicado: (2023)

3,3,5,5-Tetramethyl-r-2,c-6-diphenylpiperidin-4-one
por: Govindaraju, C., et al.
Publicado: (2012)

The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male
por: Kim, Dasohm, et al.
Publicado: (2019)

Foregut bypass vs. restrictive bariatric procedures for nonalcoholic fatty liver disease: a meta-analysis of 3,355 individuals
por: Lim, Wen Hui, et al.
Publicado: (2022)

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study
por: de Man, Femke M., et al.
Publicado: (2019)

Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
por: Narasimhan, Narayana I, et al.
Publicado: (2013)

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study
por: Whittaker, Andrew, et al.
Publicado: (2019)

Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects
por: David, Olivier J., et al.
Publicado: (2018)

Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers
por: Prothon, Susanne, et al.
Publicado: (2019)

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
por: Frost, Charles, et al.
Publicado: (2017)

No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects
por: Ross, Lisa L., et al.
Publicado: (2016)

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Influence of Cow’s Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients
por: Veerman, G. D. Marijn, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6ek8pq4s6jlcrhfr96t1s2hrm7